{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:24:00Z","timestamp":1790688240612,"version":"4.1.0"},"reference-count":175,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1I1A1A01069013"],"award-info":[{"award-number":["NRF-2020R1I1A1A01069013"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A6A1A03025124"],"award-info":[{"award-number":["NRF-2018R1A6A1A03025124"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020H1D3A1A04080389"],"award-info":[{"award-number":["NRF-2020H1D3A1A04080389"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and\/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients\u2019 overall survival and quality of life.<\/jats:p>","DOI":"10.3390\/cells11040650","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:32:30Z","timestamp":1644784350000},"page":"650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements"],"prefix":"10.3390","volume":"11","author":[{"given":"Salima","family":"Akter","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Medical Biotechnology, Bangladesh University of Health Sciences, Dhaka 1216, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ataur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Global Biotechnology & Biomedical Research Network (GBBRN), Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Nazmul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Pristine Pharmaceuticals, Patuakhali 8600, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajara","family":"Akhter","sequence":"additional","affiliation":[{"name":"Biomedical and Toxicological Research Institute, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka 1205, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Noor","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Bangladesh University of Health Sciences, Dhaka 1216, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokibul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh"},{"name":"Department of Biochemistry, College of Medicine, Hallym University, Chuncheon 24252, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonhwa","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-3149","authenticated-orcid":false,"given":"MD. Hasanur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shamim","family":"Gazi","sequence":"additional","affiliation":[{"name":"Biotechnology and Genetic Engineering Discipline, Khulna University, Khulna 9208, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Nazmul","family":"Huda","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, UAMS Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences UAMS, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-6222","authenticated-orcid":false,"given":"Nguyen Minh","family":"Nam","sequence":"additional","affiliation":[{"name":"Research Center for Genetics and Reproductive Health, School of Medicine, Vietnam National University Ho Chi Minh City, Linh Trung Ward, Thu Duc District, Ho Chi Minh City 71308, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwook","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhee","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-156X","authenticated-orcid":false,"given":"Bonglee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-1008","authenticated-orcid":false,"given":"Insug","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohun","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-9482","authenticated-orcid":false,"given":"Wonchae","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyu","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea"},{"name":"Biomedical Science Institute, Kyung Hee University, Seoul 02447, Korea"},{"name":"Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ahmed, N., Kadife, E., Raza, A., Short, M., Jubinsky, P.T., and Kannourakis, G. (2020). Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 9.","DOI":"10.3390\/cells9030719"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer Development and Metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yang, M.Q., and Elnitski, L. (2016). A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163353"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: New opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2018.05.012","article-title":"siRNA in ovarian cancer\u2014Delivery strategies and targets for therapy","volume":"283","author":"Brand","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fabbro, M., Colombo, P.-E., Leaha, C.M., Rouanet, P., Carr\u00e8re, S., Quenet, F., Gutowski, M., Mourregot, A., D\u2019Hondt, V., and Coupier, I. (2020). Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12082184"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/era.09.167","article-title":"First-line treatment of advanced ovarian cancer: Current research and perspectives","volume":"10","author":"Marchetti","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12094-019-02167-y","article-title":"Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients","volume":"22","author":"Feliu","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1158\/1535-7163.MCT-17-0131","article-title":"Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms","volume":"17","author":"Scott","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.onc.1202319","article-title":"Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a hu-man-mouse chimeric anti-EGF receptor mAb C225","volume":"18","author":"Ye","year":"1999","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1757-2215-5-22","article-title":"Involvement of autophagy in ovarian cancer: A working hypothesis","volume":"5","author":"Peracchio","year":"2012","journal-title":"J. Ovarian Res."},{"key":"ref_13","first-page":"1","article-title":"Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence","volume":"5","author":"Wang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s10637-019-00888-z","article-title":"Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies","volume":"38","author":"Doi","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.gore.2021.100787","article-title":"Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab","volume":"37","author":"Thouvenin","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Swiatly, A., Horala, A., Matysiak, J., Hajduk, J., Nowak-Markwitz, E., and Kokot, Z.J. (2018). Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082240"},{"key":"ref_17","first-page":"1","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1038\/s41598-017-08766-5","article-title":"The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer","volume":"7","author":"Matondo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kim, S.I., Jung, M., Dan, K., Lee, S., Lee, C., Kim, H.S., Chung, H.H., Kim, J.-W., Park, N.H., and Song, Y.-S. (2020). Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12040790"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fonc.2020.00319","article-title":"Novel Therapeutic Strategies for Ovarian Cancer Stem Cells","volume":"10","author":"Terraneo","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41572-019-0073-4","article-title":"Author Correction: Radiotherapy tox-icity","volume":"5","author":"Niedermann","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"572904","DOI":"10.3389\/fonc.2020.572904","article-title":"Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase\/Protein Kinase B\/Mammalian Target of Rapamycin Signaling Pathway Inhibitors","volume":"10","author":"Xia","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/08977190701773070","article-title":"HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways","volume":"25","author":"Mehta","year":"2007","journal-title":"Growth Factors"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","article-title":"PI3K-Akt pathway: Its functions and alterations in human cancer","volume":"9","author":"Osaki","year":"2004","journal-title":"Apoptosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT Pathway for Cancer Drug Discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1634\/theoncologist.2013-0333","article-title":"The Role of the PTEN\/PI3K\/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis","volume":"19","author":"Cai","year":"2014","journal-title":"Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"662232","DOI":"10.3389\/fphar.2021.662232","article-title":"AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?","volume":"12","author":"Martorana","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., and Li, Y. (2019). Inhibition of PI3K\/Akt\/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expres-sion. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5824-9"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"624498","DOI":"10.3389\/fonc.2020.624498","article-title":"SPR965, a Dual PI3K\/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer","volume":"10","author":"Tran","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1535-7163.MCT-14-0077","article-title":"Targeting JAK1\/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer","volume":"13","author":"Wen","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1038\/s41388-019-0752-3","article-title":"Signal transducer and activator of transcription (STAT)-5: An opportunity for drug development in oncohematology","volume":"38","author":"Recio","year":"2019","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","article-title":"JAK\/STAT of all trades: Linking inflammation with cancer development, tumor progression and therapy resistance","volume":"42","author":"Sabaawy","year":"2021","journal-title":"Carcinogenesis"},{"key":"ref_38","first-page":"1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1535-7163.MCT-14-0800","article-title":"Targeted Blockade of JAK\/STAT3 Signaling Inhibits Ovarian Carcinoma Growth","volume":"14","author":"Gritsina","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41419-020-02934-8","article-title":"Combined inhibition of JAK1\/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells","volume":"11","author":"She","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fonc.2014.00075","article-title":"Targeted Disrup-tion of the JAK2\/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden","volume":"4","author":"Abubaker","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1158\/0008-5472.CAN-14-2498","article-title":"IL6\/JAK1\/STAT3 Signaling Blockade in Endometrial Cancer Affects the ALDHhi\/CD126+ Stem-like Component and Reduces Tumor Burden","volume":"75","author":"Sacchetti","year":"2015","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","article-title":"Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis","volume":"30","author":"Nakayamada","year":"2016","journal-title":"BioDrugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/beta-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-Catenin Signaling, Disease, and Emerging Therapeutic Modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Teeuwssen, M., and Fodde, R. (2019). Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101658"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13048-019-0596-z","article-title":"Wnt\/beta-catenin signalling in ovarian cancer: Insights into its hyperacti-vation and function in tumorigenesis","volume":"12","author":"Nguyen","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","article-title":"The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00428-020-02760-5","article-title":"Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development","volume":"477","author":"Zannoni","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1758835920913798","DOI":"10.1177\/1758835920913798","article-title":"Inhibition of the Wnt\/beta-catenin pathway enhances antitumor immunity in ovarian cancer","volume":"12","author":"Doo","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1590\/1519-6984.228437","article-title":"Apoptosis (programmed cell death) and its signals\u2014A review","volume":"81","author":"Obeng","year":"2021","journal-title":"Braz. J. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35037710","article-title":"The biochemistry of apoptosis","volume":"407","author":"Hengartner","year":"2000","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature03098","article-title":"Intrinsic tumour suppression","volume":"432","author":"Lowe","year":"2004","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome Translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(01)00219-7","article-title":"Apoptosis: Corralling the corpses","volume":"104","author":"Hengartner","year":"2001","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc776","article-title":"Death and anti-death: Tumour resistance to apoptosis","volume":"2","author":"Igney","year":"2002","journal-title":"Nat. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Al-Alem, L.F., Baker, A.T., Pandya, U.M., Eisenhauer, E.L., and Rueda, B.R. (2019). Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111631"},{"key":"ref_63","first-page":"250","article-title":"E1A-mediated paclitaxel sensitization in HER-2\/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis in-volving the caspase-3 pathway","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1593\/tlo.09121","article-title":"Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1\/2 phosphorylation","volume":"2","author":"Brautigam","year":"2009","journal-title":"Transl. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","article-title":"Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins","volume":"121","author":"Yasmeen","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/jcb.26822","article-title":"Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK\/mTOR signaling pathway","volume":"119","author":"Liu","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2014.11.010","article-title":"Mitochondrial division inhibitor 1 (mdivi-1) enhances death re-ceptor-mediated apoptosis in human ovarian cancer cells","volume":"456","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res. Commun"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40659-019-0243-6","article-title":"Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells","volume":"52","author":"Liu","year":"2019","journal-title":"Biol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Rahman, M.A., Rahman, M.S., Rahman, M.H., Rasheduzzaman, M., Mamun-Or-Rashid, A.N.M., Uddin, M.J., Rahman, M.R., Hwang, H., Pang, M.G., and Rhim, H. (2021). Modulatory Effects of Autophagy on APP Processing as a Potential Treatment Target for Alzheimer\u2019s Disease. Biomedicines, 9.","DOI":"10.20944\/preprints202010.0195.v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5483\/BMBRep.2017.50.7.069","article-title":"Therapeutic implication of autophagy in neurodegenerative diseases","volume":"50","author":"Rahman","year":"2017","journal-title":"Bmb. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rahman, M.A., Rahman, M.H., Hossain, M.S., Biswas, P., Islam, R., Uddin, M.J., Rahman, M.H., and Rhim, H. (2020). Molecular Insights into the Multifunctional Role of Natural Compounds: Autophagy Modulation and Cancer Prevention. Biomedicines, 8.","DOI":"10.31219\/osf.io\/ahc58"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fcell.2020.00283","article-title":"Molecular Insights Into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells","volume":"8","author":"Rahman","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"18172","DOI":"10.1002\/jcb.29123","article-title":"LncRNA MEG3 contributes to adenosine-induced cytotoxicity in hepatoma HepG2 cells by downregulated ILF3 and autophagy inhibition via regulation PI3K-AKT-mTOR and beclin-1 signaling pathway","volume":"120","author":"Pu","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.3390\/ijms15045292","article-title":"Beclin 1 Expression in Ovarian Tissues and Its Effects on Ovarian Cancer Prognosis","volume":"15","author":"Cai","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ncb1730","article-title":"Regulation of autophagy by cytoplasmic p53","volume":"10","author":"Tasdemir","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ceb.2010.01.001","article-title":"The Beclin 1 interactome","volume":"22","author":"He","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_77","first-page":"5134","article-title":"Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis","volume":"22","author":"Liang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_78","first-page":"3917","article-title":"The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells","volume":"118","author":"Lu","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83476","DOI":"10.18632\/oncotarget.13080","article-title":"Autophagy as an emerging therapy target for ovarian car-cinoma","volume":"7","author":"Zhan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Abdallah, M., El-Readi, M., Althubiti, M., Almaimani, R., Ismail, A., Idris, S., Refaat, B., Almalki, W., Babakr, A., and Mukhtar, M. (2020). Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells. Molecules, 25.","DOI":"10.3390\/molecules25153355"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yexcr.2018.03.030","article-title":"SIRT3 aggravates metfor-min-induced energy stress and apoptosis in ovarian cancer cells","volume":"367","author":"Wu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3892\/ijo.2016.3552","article-title":"SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells","volume":"49","author":"Xiang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.20892\/j.issn.2095-3941.2018.0062","article-title":"Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer","volume":"15","author":"Bonello","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"\u0160kubn\u00edk, J., Pavl\u00ed\u010dkov\u00e1, V., Ruml, T., and Rimpelov\u00e1, S. (2021). Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy. Plants, 10.","DOI":"10.3390\/plants10030569"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_90","first-page":"1239","article-title":"Morphofunctional basis of the different types of angiogenesis and formation of postnatal angiogenesis-related secondary structures","volume":"32","author":"Gutierrez","year":"2017","journal-title":"Histol. Histopathol"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570161115666170105124038","article-title":"Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges","volume":"15","author":"Siveen","year":"2017","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ccr.2010.11.001","article-title":"Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization","volume":"18","author":"Tvorogov","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/bjc.2012.541","article-title":"Targeted anti-vascular therapies for ovarian cancer: Current evidence","volume":"108","author":"Hall","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","article-title":"Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors","volume":"28","author":"Lockhart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1128\/MCB.19.10.6845","article-title":"Controlled dimerization of ErbB receptors provides evidence for differential sig-naling by homo- and heterodimers","volume":"19","author":"Muthuswamy","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized an-ti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with over-expression of HER2: A phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tol-erability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tu-mours: A phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Can-cer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study","volume":"32","author":"Vergote","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.neo.2021.05.009","article-title":"p85beta alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair","volume":"23","author":"Mak","year":"2021","journal-title":"Neoplasia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal Structure of an Hsp90\u2013Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1038\/sj.onc.1210534","article-title":"Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)\/M arrest in glioblastoma cell lines","volume":"26","author":"Ferragut","year":"2007","journal-title":"Oncogene"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin","volume":"42","author":"Schulte","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_113","first-page":"3132","article-title":"Degradation of HER2 by ansamycins induces growth arrest and apop-tosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3\u2032-kinase-AKT-dependent pathway","volume":"62","author":"Munster","year":"2002","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","article-title":"Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function","volume":"277","author":"Basso","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","article-title":"Modulation of Akt kinase activity by binding to Hsp90","volume":"97","author":"Sato","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.18632\/oncotarget.1929","article-title":"Sub-lethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells","volume":"5","author":"Choi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JTO.0b013e3181753b4b","article-title":"Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer","volume":"3","author":"Langer","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2217\/fon-2020-0876","article-title":"The intravenous to oral switch of taxanes: Strategies and current clinical developments","volume":"17","author":"Vermunt","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Funston, G., Hamilton, W., Abel, G., Crosbie, E.J., Rous, B., and Walter, F.M. (2020). The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003295"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen CA125 is encoded by theMUC16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/2326-6066.CIR-15-0165","article-title":"Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence\u2013Coupled Biopanning Platform","volume":"4","author":"Frietze","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_124","first-page":"1112","article-title":"Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time?","volume":"7","author":"Wagner","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.2147\/OTT.S205950","article-title":"Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches","volume":"13","author":"Palaia","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.7717\/peerj.1489","article-title":"Drug delivery systems for ovarian cancer treat-ment: A systematic review and meta-analysis of animal studies","volume":"3","author":"Raave","year":"2015","journal-title":"PeerJ."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/bc100351n","article-title":"Chemoselective modification of turnip yellow mosaic virus by Cu(I) catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction and its application in cell binding","volume":"22","author":"Zeng","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.msec.2014.06.002","article-title":"Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review","volume":"45","author":"Ye","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.addr.2006.09.014","article-title":"Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imaging","volume":"58","author":"Manchester","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Levit, S., and Tang, C. (2021). Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer. Nanomaterials, 11.","DOI":"10.3390\/nano11041048"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2174\/1871520621666210204201347","article-title":"Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers","volume":"21","author":"Kumar","year":"2021","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: Current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1039\/C6CS00177G","article-title":"Protein cages and synthetic polymers: A fruitful symbiosis for drug delivery applications, bionanotechnology and materials science","volume":"45","author":"Rother","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Holditch, S.J., Brown, C.N., Lombardi, A.M., Nguyen, K.N., and Edelstein, C.L. (2019). Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123011"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"12435","DOI":"10.1073\/pnas.1007026107","article-title":"Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy","volume":"107","author":"Paraskar","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/acs.langmuir.7b02354","article-title":"Surface Modification of Cispla-tin-Complexed Gold Nanoparticles and Its Influence on Colloidal Stability, Drug Loading, and Drug Release","volume":"34","author":"Tan","year":"2018","journal-title":"Langmuir"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1759-7714.2012.00113.x","article-title":"Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study","volume":"3","author":"Yuan","year":"2012","journal-title":"Thorac. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: Clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-009-1099-1","article-title":"Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane","volume":"65","author":"Feng","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1016\/j.biomaterials.2013.03.017","article-title":"Cucumber mosaic virus as drug delivery vehicle for doxorubicin","volume":"34","author":"Zeng","year":"2013","journal-title":"Biomaterials"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","article-title":"Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy","volume":"24","author":"Qi","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2017.09.060","article-title":"Co-delivery strategies to overcome multidrug resistance in ovarian cancer","volume":"533","author":"Khan","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/ijc.22886","article-title":"Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer","volume":"121","author":"Devalapally","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","article-title":"RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy","volume":"340","author":"Sheikh","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/1078-0432.CCR-13-1536","article-title":"Targeted nanomedicine for sup-pression of CD44 and simultaneous cell death induction in ovarian cancer: An optimal delivery of siRNA and anticancer drug","volume":"19","author":"Shah","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1021\/acs.biomac.0c00438","article-title":"Recent Advances of Polycationic siRNA Vectors for Cancer Therapy","volume":"21","author":"Bholakant","year":"2020","journal-title":"Biomacromolecules"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer popu-lation screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strat-egies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","article-title":"Platinum drugs and taxanes: Can we overcome resistance?","volume":"7","author":"Sazonova","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1179299X19860815","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy Resistance in Advanced Ovarian Cancer Patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark. Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fonc.2020.00764","article-title":"Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance","volume":"10","author":"Cho","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/bjc.2016.379","article-title":"microRNA-137 promotes apoptosis in ovarian cancer cells via the regu-lation of XIAP","volume":"116","author":"Li","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1159\/000495492","article-title":"Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC\/Q-TOF MS","volume":"51","author":"Yang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"15662","DOI":"10.18632\/oncotarget.3525","article-title":"Prognostic value of a 92-probe signature in breast cancer","volume":"6","author":"Akter","year":"2015","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13148-021-01149-8","article-title":"Transcriptional epigenetic regulation of Fkbp1\/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer","volume":"13","author":"Soto","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ijc.29690","article-title":"RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer","volume":"138","author":"Steinbach","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-017-0536-y","article-title":"FOXM1 expression is significantly as-sociated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients","volume":"36","author":"Tassi","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Ad-vanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"er al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (EN-GOT-OV16\/NOVA): Results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMe1914488","article-title":"Personalized Medicine for Primary Treatment of Serous Ovarian Cancer","volume":"381","author":"Longo","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3892\/ijo.2014.2627","article-title":"Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer","volume":"45","author":"Yeh","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_168","first-page":"984","article-title":"PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Genet."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13148-021-01006-8","article-title":"CAMK2N1\/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients","volume":"13","author":"Heinze","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1038\/onc.2013.307","article-title":"COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer","volume":"33","author":"Wu","year":"2013","journal-title":"Oncogene"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.omtn.2019.12.005","article-title":"circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Lee, J., Kim, S., Oh, Y., Kim, J., Lee, S., and Chae, H. (2021). Increased Expression of Retinol-Binding Protein 4 in Ovarian Endometrioma and Its Possible Role in the Pathogenesis of Endometriosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115827"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"97851","DOI":"10.18632\/oncotarget.18415","article-title":"Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients","volume":"8","author":"Avril","year":"2017","journal-title":"Oncotarget"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Mukherjee, S., Sundfeldt, K., Borrebaeck, C., and Jakobsson, M. (2021). Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. Proteomes, 9.","DOI":"10.3390\/proteomes9020025"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2017.08.003","article-title":"Epigenetics in ovarian cancer","volume":"51","author":"Natanzon","year":"2017","journal-title":"Semin. Cancer Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:50Z","timestamp":1760134730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":175,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11040650"],"URL":"https:\/\/doi.org\/10.3390\/cells11040650","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,13]]}}}